BALCHEM CORP

BCPC 10-Q · Q1 2026
API behind this page

BCPC Q1 2026 request

Playground key active
Request URL /api/financials?ticker=BCPC&year=2026&quarter=1
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q1 2026 Q1 2025 YoY
Revenue 270,709 250,519 +8.1%
Show Product Lines breakouts
Product Sales Revenue 270,216 250,061 +8.1%
Royalty 493 458 +7.6%
Show Business Segments breakouts
Animal Nutrition and Health · Operating Segments 62,189 57,277 +8.6%
Human Nutrition and Health · Operating Segments 171,628 158,457 +8.3%
Specialty Products · Operating Segments 34,727 33,275 +4.4%
Show Geography breakouts
Non Us 73,327 64,797 +13.2%
US 197,382 185,722 +6.3%
Show Consolidation Items breakouts
Corporate Non Segment 2,165 1,510 +43.4%
Cost of Revenue 169,625 162,351 +4.5%
Show Product Lines breakouts
Raw materials sold · Corporate Joint Venture 9,951 9,925 +0.3%
Services provided · Corporate Joint Venture 1,117 1,127 -0.9%
Show Business Segments breakouts
Animal Nutrition and Health · Operating Segments 47,200 44,917 +5.1%
Human Nutrition and Health · Operating Segments 105,772 99,383 +6.4%
Specialty Products · Operating Segments 14,264 15,986 -10.8%
Show Consolidation Items breakouts
Corporate Non Segment 2,389 2,065 +15.7%
Show Related Party Transactions By Related Party breakouts
Corporate Joint Venture 8,045 7,918 +1.6%
Gross Profit 101,084 88,168 +14.6%
Show Business Segments breakouts
Animal Nutrition and Health · Operating Segments 14,989 12,360 +21.3%
Human Nutrition and Health · Operating Segments 65,856 59,074 +11.5%
Specialty Products · Operating Segments 20,463 17,289 +18.4%
Show Consolidation Items breakouts
Corporate Non Segment -224 -555 +59.6%
Selling Expense 21,096 16,926 +24.6%
Research & Development 5,881 4,662 +26.1%
General & Administrative 18,481 15,565 +18.7%
Operating Expenses 45,458 37,153 +22.4%
Show Business Segments breakouts
Animal Nutrition and Health · Operating Segments 9,297 7,124 +30.5%
Human Nutrition and Health · Operating Segments 25,836 21,100 +22.4%
Specialty Products · Operating Segments 8,528 7,704 +10.7%
Show Consolidation Items breakouts
Corporate Non Segment 1,797 1,225 +46.7%
Operating Income 55,626 51,015 +9.0%
Show Business Segments breakouts
Animal Nutrition and Health · Operating Segments 5,692 5,236 +8.7%
Human Nutrition and Health · Operating Segments 40,020 37,974 +5.4%
Specialty Products · Operating Segments 11,935 9,585 +24.5%
Show Consolidation Items breakouts
Corporate Non Segment -2,021 -1,780 -13.5%
Interest Income Expense Nonoperating Net 2,213 2,924 -24.3%
Other Non-Operating Income (Expense) 891 151 +490.1%
Non-Operating Income (Expense) 3,104 3,075 +0.9%
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments 52,522 47,940 +9.6%
Income Tax Expense (Benefit) 12,237 10,887 +12.4%
Net Income 40,285 37,053 +8.7%
Show Equity Components breakouts
Retained Earnings 40,285 37,053 +8.7%
EPS (Basic) 1.26 1.14 +10.5%
EPS (Diluted) 1.25 1.13 +10.6%
Comprehensive Income 30,487 58,537 -47.9%
Other Comprehensive Income -9,798 21,484 -145.6%
Show Equity Components breakouts
Accumulated Defined Benefit Plans Adjustment 304 — —
Accumulated Other Comprehensive Income -9,798 21,484 -145.6%
Accumulated Translation Adjustment -10,102 — —
Wtd Avg Shares (Basic) 31,937 32,440 -1.6%
Wtd Avg Shares (Diluted) 32,284 32,807 -1.6%
Income Loss From Equity Method Investments (Q) — — —
Show Schedule Of Equity Method Investment Equity Method Investee Name breakouts
St. Gabriel CC Company, LLC 124 122 +1.6%

Balance Sheet

Balance Sheet
Metric Q1 2026 Q1 2025 YoY
Current Assets
Cash & Cash Equivalents 72,873 49,901 +46.0%
Accounts Receivable 154,232 130,447 +18.2%
Show Related Party Transactions By Related Party breakouts
Corporate Joint Venture 4,454 3,824 +16.5%
Inventory 146,743 144,926 +1.3%
Other Prepaid Expense Current 8,955 8,132 +10.1%
Other Assets Current 6,138 — —
Show Related Party Transaction breakouts
Non-contractual Monies Owed · Corporate Joint Venture 150 — —
Total Current Assets 388,941 340,239 +14.3%
Non-Current Assets
Property, Plant & Equipment 303,070 283,753 +6.8%
Goodwill 811,452 793,087 +2.3%
Intangible Assets 127,678 165,965 -23.1%
Operating Lease Right-of-Use Assets 13,661 15,598 -12.4%
Other Non-Current Assets 18,687 17,235 +8.4%
Total Assets 1,693,742 1,617,555 +4.7%
Show Business Segments breakouts
Animal Nutrition and Health · Operating Segments 181,036 169,464 +6.8%
Human Nutrition and Health · Operating Segments 1,250,779 1,213,407 +3.1%
Specialty Products · Operating Segments 169,768 166,745 +1.8%
Show Consolidation Items breakouts
Corporate Non Segment 92,159 67,939 +35.6%
Other Assets
Other Intangible Assets Net 28,784 — —
Finance Lease Right Of Use Asset 1,469 1,678 -12.5%
Current Liabilities
Accounts Payable Trade Current 70,729 65,975 +7.2%
Show Related Party Transaction breakouts
Non-contractual Monies Owed · Corporate Joint Venture 296 296 0.0%
Accrued Liabilities 51,820 44,172 +17.3%
Employee Related Liabilities Current 12,698 11,631 +9.2%
Dividends Payable Current 169 126 +34.1%
Taxes Payable Current 13,473 13,728 -1.9%
Operating Lease Liability Current 3,444 3,726 -7.6%
Finance Lease Liability Current 207 197 +5.1%
Total Current Liabilities 152,540 139,555 +9.3%
Non-Current Liabilities
Deferred Tax Liabilities 53,376 45,217 +18.0%
Operating Lease Liabilities 10,571 12,445 -15.1%
Finance Lease Liability Noncurrent 1,492 1,698 -12.1%
Other Long Term Debt Noncurrent 21,647 19,939 +8.6%
Total Liabilities 408,626 408,854 -0.1%
Other Liabilities
Long Term Line Of Credit 169,000 190,000 -11.1%
Stockholders' Equity
Common Stock 2,143 2,175 -1.5%
Additional Paid-In Capital 89,543 174,243 -48.6%
Retained Earnings 1,161,681 1,034,546 +12.3%
Accumulated Other Comprehensive Income 31,749 -2,263 +1503.0%
Total Stockholders' Equity 1,285,116 1,208,701 +6.3%
Show Equity Components breakouts
Accumulated Defined Benefit Plans Adjustment 498 — —
Accumulated Other Comprehensive Income 31,749 -2,263 +1503.0%
Accumulated Translation Adjustment 31,251 — —
Additional Paid In Capital 89,543 174,243 -48.6%
Common Stock 2,143 2,175 -1.5%
Retained Earnings 1,161,681 1,034,546 +12.3%
Total Liabilities & Equity 1,693,742 1,617,555 +4.7%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q1 2026 YTD Q1 2025 YoY
Operating Activities
Depreciation & Amortization 12,491 11,014 +13.4%
Show Business Segments breakouts
Animal Nutrition and Health · Operating Segments 1,859 1,761 +5.6%
Human Nutrition and Health · Operating Segments 8,647 7,303 +18.4%
Specialty Products · Operating Segments 1,755 1,726 +1.7%
Show Consolidation Items breakouts
Corporate Non Segment 230 224 +2.7%
Stock-Based Compensation 5,356 3,810 +40.6%
Deferred Income Taxes -187 -115 -62.6%
Provision For Doubtful Accounts 289 -79 +465.8%
Unrealized Gain Loss On Foreign Currency Transactions And Deferred Compensation 717 24 +2887.5%
Gain Loss On Sales Of Assets And Asset Impairment Charges 151 65 +132.3%
Change in Accounts Receivable -11,409 -10,069 -13.3%
Change in Inventory -16,216 -12,897 -25.7%
Change in Prepaid & Other Assets 763 -859 +188.8%
Increase Decrease In Accounts Payable And Accrued Liabilities -1,554 -737 -110.9%
Increase Decrease In Accrued Income Taxes Payable 9,487 9,123 +4.0%
Other Operating Activities Cash Flow Statement -112 124 -190.3%
Net Cash from Operations 40,061 36,457 +9.9%
Investing Activities
Payments To Acquire Other Productive Assets -6,252 -5,559 -12.5%
Proceeds From Sale Of Property Plant And Equipment 2 — —
Payments To Acquire Interest In Subsidiaries And Affiliates -42 -30 -40.0%
Net Cash from Investing -6,292 -5,912 -6.4%
Financing Activities
Proceeds From Lines Of Credit 52,000 29,000 +79.3%
Repayments Of Long Term Lines Of Credit -47,000 -29,000 -62.1%
Finance Lease Principal Payments -51 -49 -4.1%
Proceeds From Stock Options Exercised 6,727 1,668 +303.3%
Payments Of Dividends -30,769 -28,263 -8.9%
Share Repurchases -15,690 -5,325 -194.6%
Net Cash from Financing -34,783 -31,969 -8.8%
Amortization of Financing Costs 71 71 0.0%
Supplemental
Income Taxes Paid 1,394 1,443 -3.4%
Interest Paid 2,320 3,010 -22.9%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents -683 1,810 -137.7%
Net Change in Cash -1,697 386 -539.6%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 72,873 49,901 +46.0%

Values in thousands USD. Source: SEC EDGAR 10-Q filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key